Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production

Reuters

11/03

<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production

Ginkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580562213"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580562213\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580562213?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580562213","market":"us","top_or_hot":-1,"title":"Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNA","symbol_name":"Ginkgo Bioworks Holdings Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2qFrhF:1","article_id":"2580562213","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580562213","pubTimestamp":1762174979,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ginkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's  Biopharmaceutical Manufacturing Preparedness Consortium . The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNA":"Ginkgo Bioworks Holdings Inc.","BK4161":"工业机械","BK4139":"生物科技","BK4121":"生命科学工具和服务","DCI":"唐纳森","BK4109":"特种化学制品"},"translate_title":"Ginkgo Bioworks赢得价值2220万美元的BARDA抗丝状病毒抗体生产合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCI":0.9,"DNA":0.9},"content_text":"Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    \n\nGinkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}